KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema.

Igor Kozak, Diana V Do, Hongxin Lai, Miller J Ogidigben, Francisco J López

Ophthalmol Sci 5(5) 100833

PMID40688490
PMCIDPMC12271896
DOI10.1016/j.xops.2025.100833
发表日期2025-07-21
摘要

摘要

PURPOSE: Time in range (TIR) is a novel end point that assesses the time during which an outcome remains within a predetermined range. Because the range includes normal parameters, it is indicative of clinically meaningful benefit. The MEAD trial comprised two 3-year randomized, multicenter, sham-controlled, phase III clinical studies that evaluated the efficacy and safety of dexamethasone intravitreal implant (DEX-I) in patients with diabetic macular edema. Dexamethasone intravitreal implant significantly improved best-corrected visual acuity (BCVA) and central retinal thickness (CRT) compared with sham treatment. We present a post hoc analysis of the MEAD trial to investigate TIR benefit across various thresholds of BCVA and CRT with DEX-I versus sham. DESIGN: Post hoc analysis of results from the randomized, multicenter, sham-controlled, phase III MEAD trial (NCT00168337 and NCT00168389). PARTICIPANTS: Adults with type 1 or 2 diabetes mellitus and fovea-involved macular edema associated with diabetic retinopathy. INTERVENTION: Intravitreal injection of DEX-I 0.7 mg or sham procedure. MAIN OUTCOME MEASURES: Time in range during year 1 was evaluated using BCVA thresholds of ≥69, ≥51, ≥59, and ≥64 letters, and CRT thresholds of <300, <353, <446, and <551 μm (the latter cutoffs being quartile [Q] 1, Q2, and Q3 of pooled baseline BCVA and CRT, respectively). RESULTS: Dexamethasone intravitreal implant 0.7 mg was associated with a statistically significant longer TIR versus sham at the BCVA ≥69-letter threshold (15.0 vs. 9.1 weeks, respectively; P < 0.001) and the CRT <300 μm threshold (18.5 vs. 8.3 weeks, respectively; P < 0.001). Dexamethasone intravitreal implant was also associated with longer TIR versus sham at thresholds of BCVA ≥59 (greater than or equal to Q2) and ≥64 letters (greater than or equal to Q3) and CRT <353 μm (less than Q1), <446 μm (less than Q2), and <551 μm (less than Q3) (all P < 0.001). CONCLUSIONS: Patients receiving intravitreal DEX-I 0.7 mg had a longer time with BCVA above the driving threshold and below the normal limit of CRT during year 1 of the MEAD trial versus those who received sham. These results suggest that patients treated with dexamethasone experience a longer time with clinically meaningful outcomes than with sham, such as being able to drive or regaining normal structural retinal features. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。